Myeloid leukemia: are we getting better?  by Hamerschlak, Nelson
SM
N
H
a
A
A
T
R
r
r
2
t
l
e
p
w
C
i
o
p
t
i
t
a
m
p
s
i
7
0
h
1
rrev bras hematol hemoter. 2 0 1 5;3  7(1):3–4
Revista Brasileira de Hematologia e Hemoterapia
Brazilian Journal of Hematology and Hemotherapy
www.rbhh.org
cientiﬁc comment
yeloid  leukemia:  are we  getting  better?
elson Hamerschlak ∗
ospital Israelita Albert Einstein, São Paulo, SP, Brazil
 r  t  i  c  l  e  i  n  f  orticle history:
vailable online 21 November 2014
short time. There is a need to provide a post remission ther-he study by Callera et al., published in this issue of the
evista Brasileira de Hematologia e Hemoterapia (RBHH),1
eveals evidence of a continuous decrease in the mortality
ate in adult patients with myeloid leukemias from 1994 to
011 in southeast Brazil. Undoubtedly, this decline is related
o the better understanding and treatment of chronic myeloid
eukemia (CML), acute myeloid leukemia (AML) and promy-
locytic leukemia (APL, M3).2–4 The words myeloid retirar a
alavra and leukemia refer to a very wide range of disorders
ith varying severity and manifestations. We address here
ML, AML  and APL mainly to better understand the advances
n each of them.
I  believe that there is really a trend in Brazil to follow devel-
ped countries which have reported signiﬁcant changes in
rognosis. Unfortunately, we still experience many  difﬁcul-
ies, but we  have had progress as well: ﬁrst, tyrosine kinase
s widely distributed to patients with CML  in Brazil; second,
he health authorities have just opened a public consultation
bout AML  treatment, including cytogenetics and the recom-
endation for the use of molecular tests in the treatment
rotocol; and third, the results of treatments of LPA show sub-
tantial improvement.3Evolution in the treatment of leukemia has greatly
mproved the chances of cure and disease control. More than
500 people develop leukemia in the country today and 9000
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eserved.people die of the disease every year in Brazil according to
the National Cancer Institute (INCA). Despite the lethality,
leukemia is now a curable type of cancer.
Prognosis of leukemia patients today is generally good. CML
is controlled with a daily pill and acute leukemias are cured in
50–80% of cases. In recent years, great advances have been
made in treatment, including chemotherapy, bone marrow
transplantation and targeted-treatments.2 The introduction
of tyrosine kinase inhibitors in the treatment of CML, which
was previously treated with transplantation, is an evolution. In
addition, greater knowledge of the genetics behind the disease
leads to better choices and individualization of treatment.
These improvements in treatment have increased chances
of cure and disease control, and better quality of life for the
patients. Hence, the most used treatment for CML  today is
targeted therapy with the drugs imatinib, dasatinib or niloti-
nib. The treatment must be continued for life, ensuring that
the person stays in remission while taking the drugs. This is
called functional cure.2
For acute cases, treatment is planned in stages. First
chemotherapy is proposed, usually with a good result for a Ensino e Pesquisa Albert Einstein, Av. Albert Einstein, 627/520,
apy. During this period, certain combined drugs are used to
extend and maintain disease remission. In AML, the main
induction regimen (3 + 7) has been used for more  than 40 years.
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For cases with good prognosis, consolidation chemotherapy
or autologous transplantation has been used. For cases with
bad prognosis or when relapse occurs, allogeneic bone mar-
row transplants have brought good results. These procedures
today are very safe and recommended.3
Thus, a cytogenetic evaluation that addresses the so-called
molecular factors, in particular FMS-like tyrosine kinase-3
(FLT3), nucleophosmin (NPM1) and Cantharidin-binding pro-
tein (CBP) alpha subunit, is essential, as they allocate patients
to receive consolidation with chemotherapy and/or autolo-
gous transplants, when prognosis is favorable, or to undergo
allogeneic transplants in cases of poor prognosis. Proper use
of algorithms improves prognosis.3
Elderly patients, among whom leukemia is more  prevalent,
started to be treated more  aggressively, just like young peo-
ple, because the infrastructure of care has improved greatly in
recent years. This yields a high rate of remission and, in those
patients with better performance status and lower rates of
fragility, the possibility of undergoing low toxicity, allogeneic,
non-myeloablative transplantation. Data from our group in
partnership with MD  Anderson Hospital show results in the
elderly similar to those obtained with younger patients.5 Fur-
thermore, the advent of hypomethylating agents opens new
perspectives for the treatment of AML  in elderly patients.6–8
Finally, the effort in Brazil to improve the care of patients
with APL through the program headed by Dr. Eduardo Rego
using a Brazilian protocol based on that of the Spanish group
(PETHEMA), brought our outcomes up to international levels.4
For all that, hopefully, in a few years, myeloid leukemias will
be curable diseasesConﬂicts  of  interest
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